Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel
plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators
would like to determine the percentage of patients with squamous cell lung cancers who
experience shrinkage of their tumors following treatment with this regimen. This combination
of drugs is not a standard therapy for patients with squamous cell lung cancers. However,
each of these drugs, when given alone or with other chemotherapies, is FDA-approved for the
treatment of this disease.